Skip to main content

Table 1 Trends of malaria intervention coverage indicators, Mali, 2000–2015

From: Impact evaluation of malaria control interventions on morbidity and all-cause child mortality in Mali, 2000–2012

Interventions 2001
% (95% CI)
N
2006
% (95% CI)
N
2010
% (95% CI)
N
2012–2013
 % (95% CI)
N
2015
% (95% CI)
N
Changea p£
Nets
 Household ownership n/a 40.5 (37.3–42.7)
31,910
62.9 (60.3–65.4)
7883
70.6 (69.4–71.8)
47,829
n/a 30.1 < 0.0001
ITNs
 Household ownership ≥1 n/a 49.4 (46.6–52.2)
11,109
87.2 (84.1–89.7)
1428
84.4 (83.1–85.6)
10,105
93.0 (91.8–94.1)
4240
43.6 < 0.0001
 Use (children < 5 yrs) n/a 26.4 (24.0–29.0)
11,640
72.6 (68.2–76.7)
1801
69.0 (67.2–70.7)
10,634
71.2 (68.9–69.6)
7880
44.8 < 0.0001
 Use (pregnant women) n/a 27.6 (23.4–32.2)
1677
  73.2 (69.6–76.5)
1200
77.9 (74.4–81.0)
774
50.3 < 0.0001
 Use (all persons) n/a 20.7 (18.9–22.5)
61,758
56.9 (53.8–59.9)
8721
60.5 (59.0–62.0)
55,836
63.9 (62.0–65.8)
37,755
43.2 < 0.001
IPTp during last pregnancy
 2+ doses n/a 10.1 (8.6–12.0)
4989
NA 28.5 (26.3–30.9)
3965
37.8 (34.5–41.1)
3017
27.7 < 0.0001
Recommended first-line malaria treatment
  92.4* (90.0–94.3) 1049 5.5b (3.6–8.3)
677
23.3c (15.8–32.9)
241
19.0c (13.4–26.3)
187
28.9c (23.0–35.8)
590
5.6 0.0171
  1. * Chloroquine used as first-line therapy in 2001
  2. £ P value of Chi squared for the two time points indicating the changes above
  3. aAbsolute change from 2006 to 2015, except for recommended first-line malaria treatment where 2010 was the starting point
  4. bSulfadoxine-pyrimethamine used in 2006
  5. cArtemisinin combination therapy used in 2010, 2012–2013, and 2015